MCID: KDN018
MIFTS: 65

Kidney Disease

Categories: Nephrological diseases, Genetic diseases

Aliases & Classifications for Kidney Disease

Summaries for Kidney Disease

MedlinePlus : 41 healthy kidneys clean your blood by removing excess fluid, minerals, and wastes. they also make hormones that keep your bones strong and your blood healthy. but if the kidneys are damaged, they don't work properly. harmful wastes can build up in your body. your blood pressure may rise. your body may retain excess fluid and not make enough red blood cells. this is called kidney failure. if your kidneys fail, you need treatment to replace the work they normally do. the treatment options are dialysis or a kidney transplant. each treatment has benefits and drawbacks. no matter which treatment you choose, you'll need to make some changes in your life, including how you eat and plan your activities. but with the help of health care providers, family, and friends, most people with kidney failure can lead full and active lives. nih: national institute of diabetes and digestive and kidney diseases

MalaCards based summary : Kidney Disease, also known as kidney diseases, is related to iga glomerulonephritis and primary hyperoxaluria, and has symptoms including polyuria An important gene associated with Kidney Disease is CEP290 (Centrosomal Protein 290). The drugs Perindopril and Valsartan have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and liver, and related phenotypes are homeostasis/metabolism and cardiovascular system

Disease Ontology : 12 A urinary system disease that is located in the kidney.

Wikipedia : 72 Kidney disease, also known as nephropathy or renal disease, is damage to or disease of a kidney.... more...

Related Diseases for Kidney Disease

Diseases in the Kidney Disease family:

Acute Kidney Failure Chronic Kidney Failure
Renal Infectious Disease Ren-Related Kidney Disease

Diseases related to Kidney Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 569)
id Related Disease Score Top Affiliating Genes
1 iga glomerulonephritis 31.7 ALB REN
2 primary hyperoxaluria 30.7 ACE REN
3 choroiditis 30.3 ACE ALB UMOD
4 cystinosis 30.3 ACE ALB REN UMOD
5 acute liver failure 29.9 ALB B2M CST3 REN
6 calcinosis 29.5 ACE ALB B2M CST3 EPO PKDREJ
7 autosomal dominant polycystic kidney disease 12.3
8 cystic kidney disease 12.2
9 polycystic kidney disease 4, with or without hepatic disease 12.2
10 epilepsy, progressive myoclonic 4, with or without renal failure 12.2
11 polycystic kidney disease 12.2
12 polycystic kidney disease 1 12.2
13 polycystic kidney disease 2 12.2
14 hyperuricemia, pulmonary hypertension, renal failure, and alkalosis 12.1
15 medullary cystic kidney disease 2 12.1
16 autosomal dominant medullary cystic kidney disease with hyperuricemia 12.1
17 bifid nose with or without anorectal and renal anomalies 12.1
18 autosomal dominant medullary cystic kidney disease without hyperuricemia 12.1
19 medullary cystic kidney disease 1 12.0
20 polycystic kidney disease 3 12.0
21 ventriculomegaly with cystic kidney disease 12.0
22 polycystic kidney disease, infantile severe, with tuberous sclerosis 12.0
23 glomerulocystic kidney disease with hyperuricemia and isosthenuria 12.0
24 autosomal dominant tubulointerstitial kidney disease, muc1-related 12.0
25 autoimmune interstitial lung, joint, and kidney disease 12.0
26 structural heart defects and renal anomalies syndrome 12.0
27 ren-related kidney disease 11.9
28 chronic kidney failure 11.9
29 polycystic kidney disease 5 11.9
30 autosomal dominant tubulointerstitial kidney disease, umod-related 11.8
31 igg4-related kidney disease 11.8
32 malignant hypertensive renal disease 11.8
33 nephronophthisis 11.7
34 polycyctic kidney disease 3 11.7
35 autosomal dominant tubulointerstitial kidney disease, ren-related 11.7
36 polycystic kidney disease 1, autosomal dominant 11.7
37 polycystic kidney disease 2, autosomal dominant 11.7
38 familial juvenile hyperuricaemic nephropathy 11.6
39 renal osteodystrophy 11.5
40 renal cysts and diabetes syndrome 11.3
41 gillessen-kaesbach-nishimura syndrome 11.1
42 alport syndrome 11.1
43 neuropathy, hereditary sensory, type if 11.0 PKD1 PKD2 PKDREJ
44 end stage renal failure 11.0
45 thyroid dyshormonogenesis 1 11.0 PKD1 PKD2 PKHD1
46 lymphoplasmacytic lymphoma 11.0 PKD1 PKD2 PKDREJ PKHD1
47 caroli disease 10.9
48 x-linked sideroblastic anemia with ataxia 10.9 PKD1L1 PKD2 PKDREJ
49 glomerulonephritis 10.9
50 polycystic liver disease 10.9

Comorbidity relations with Kidney Disease via Phenotypic Disease Network (PDN): (show top 50) (show all 54)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Myocardial Infarction
Alzheimer Disease Bladder Neck Obstruction
Bronchitis Bronchopneumonia
Cardiac Arrest Cardiogenic Shock
Chronic Kidney Failure Chronic Myocardial Ischemia
Decubitus Ulcer Deficiency Anemia
Diabetic Polyneuropathy Encephalopathy
Esophagitis Familial Atrial Fibrillation
First-Degree Atrioventricular Block Generalized Atherosclerosis
Gout Heart Disease
Hydronephrosis Hypertension, Essential
Hypoglycemia Hypoglycemic Coma
Hypothyroidism Intermediate Coronary Syndrome
Intestinal Obstruction Iron Deficiency Anemia
Ischemic Heart Disease Left Ventricular Outflow Tract Obstruction
Malignant Essential Hypertension Microvascular Complications of Diabetes 1
Mitral Valve Disease Nephrosclerosis
Paralytic Ileus Peripheral Vascular Disease
Polycystic Kidney Disease Prostate Cancer
Prostatic Hypertrophy Protein-Energy Malnutrition
Pulmonary Hypertension, Familial Primary, 1, with or Without Hht Pyelonephritis
Renal Artery Atheroma Renal Artery Disease
Respiratory Failure Schizophreniform Disorder
Sinoatrial Node Disease Swallowing Disorders

Graphical network of the top 20 diseases related to Kidney Disease:



Diseases related to Kidney Disease

Symptoms & Phenotypes for Kidney Disease

UMLS symptoms related to Kidney Disease:


polyuria

MGI Mouse Phenotypes related to Kidney Disease:

44 (show all 11)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.31 ALB B2M CASR CEP290 COL4A5 CST3
2 cardiovascular system MP:0005385 10.27 ACE B2M CEP290 COL4A5 CST3 EPO
3 mortality/aging MP:0010768 10.17 IFT88 PKD1 PKD1L1 PKD2 PKHD1 REN
4 hematopoietic system MP:0005397 10.16 ACE B2M CASR CEP290 COL4A5 EPO
5 immune system MP:0005387 10.14 ACE B2M CASR CEP290 COL4A5 EPO
6 digestive/alimentary MP:0005381 10.08 ALB B2M CASR IFT88 PKD1 PKD1L1
7 liver/biliary system MP:0005370 10.02 B2M CEP290 EPO IFT88 PKD1 PKD2
8 renal/urinary system MP:0005367 9.93 ACE ALB CASR CEP290 COL4A5 IFT88
9 normal MP:0002873 9.86 CEP290 EPO PKD1 PKD1L1 PKD2 PKHD1
10 reproductive system MP:0005389 9.61 PKHD1 REN ACE B2M CEP290 CST3
11 respiratory system MP:0005388 9.17 CEP290 EPO IFT88 PKD1 PKD1L1 PKD2

Drugs & Therapeutics for Kidney Disease

Drugs for Kidney Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1516)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Perindopril Approved Phase 4,Phase 3,Phase 2 107133-36-8, 82834-16-0 107807
2
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 137862-53-4 60846
3
Pitavastatin Approved Phase 4 147511-69-1, 147526-32-7 6366718 5282452
4
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 79902-63-9 54454
5
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3 76-42-6 5284603
6
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 616-91-1 12035
7
Moxonidine Approved Phase 4 75438-57-2 4810
8
Enalapril Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 75847-73-3 5362032 40466924
9
Enalaprilat Approved Phase 4,Phase 3,Phase 2,Phase 1 76420-72-9 6917719
10
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
11
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
12
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 174722-31-7 10201696
13
Acarbose Approved, Investigational Phase 4,Phase 3 56180-94-0 441184
14
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 111025-46-8 4829
15
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7439-89-6 23925
16
Ezetimibe Approved Phase 4,Phase 2,Phase 1 163222-33-1 150311
17
Spironolactone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1952-01-7, 52-01-7 5833
18
Amlodipine Approved Phase 4,Phase 3,Phase 2,Early Phase 1 88150-42-9 2162
19
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-78-2 2244
20
Atenolol Approved Phase 4,Phase 3,Early Phase 1 29122-68-7 2249
21
Clonidine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 4205-90-7 2803
22
Doxazosin Approved Phase 4,Phase 3 74191-85-8 3157
23
Furosemide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 54-31-9 3440
24
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-93-5 3639
25
Irbesartan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 138402-11-6 3749
26
Ramipril Approved Phase 4,Phase 3,Phase 2 87333-19-5 5362129
27
Ticagrelor Approved Phase 4,Phase 3,Phase 1,Phase 2 274693-27-5 9871419
28
Ticlopidine Approved Phase 4,Phase 3,Phase 2,Phase 1 55142-85-3 5472
29
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
30
Alprostadil Approved, Investigational Phase 4 745-65-3 149351
31
Everolimus Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 159351-69-6 6442177
32
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
33
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
34
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 104987-11-3 445643 439492
35
Candesartan Approved Phase 4,Phase 3,Phase 2,Phase 1 139481-59-7 2541
36
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1 10102-43-9 145068
37
Digoxin Approved Phase 4 20830-75-5 30322 2724385
38
Peginterferon alfa-2b Approved Phase 4,Phase 2,Phase 1 99210-65-8, 215647-85-1
39
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1 36791-04-5 37542
40
Fluvastatin Approved Phase 4,Phase 3,Phase 2 93957-54-1 1548972
41
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 53-03-2 5865
42
Benzocaine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 1994-09-7, 94-09-7 2337
43
alemtuzumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 216503-57-0
44
Daclizumab Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 152923-56-3
45
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 128794-94-5 5281078
46
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 24280-93-1 446541
47
Cilnidipine Approved Phase 4,Phase 2 132203-70-4 5282138
48
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3 76631-46-4, 113775-47-6 68602 5311068 56032
49
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 2078-54-8 4943
50
Azathioprine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 446-86-6 2265

Interventional clinical trials:

(show top 50) (show all 9105)

id Name Status NCT ID Phase Drugs
1 Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease Unknown status NCT02299310 Phase 4 Valsartan;Perindopril
2 The Effect and Safety of the Seasonal Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Not on Dialysis Unknown status NCT02105519 Phase 4
3 Keto-/Amino Acid Supplemented Low Protein Diet in Patients With Chronic Kidney Disease Unknown status NCT00364884 Phase 4 ketoaminoacid
4 The Prevention of Contrast Induced Nephropathy by Sarpogrelate in Patients With Chronic Kidney Disease Unknown status NCT01165567 Phase 4 sarpogrelate
5 Folic Acid for Prevention of Contrast Induced Nephropathy Unknown status NCT02444013 Phase 4 Folic acid;Placebo
6 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease Unknown status NCT01155128 Phase 4
7 Vitamin K2 and Vessel Calcification in Chronic Kidney Disease Patients Unknown status NCT01101698 Phase 4 Vitamin K2+10μg cholecalciferol;Vitamin D
8 Preventive Effect of Pitavastatin on Contrast-Induced Nephropathy in Patients With Renal Dysfunction Unknown status NCT01871792 Phase 4 Pitavastatin;Placebo
9 Efficacy and Safety of Simvast Controlled Release (CR) and Zocor in Chronic Kidney Disease(CKD) Stage 3, 4 and 5 Patients With Hyperlipidemia Unknown status NCT01564875 Phase 4 Simvast CR;Zocor
10 Opioids in Chronic Kidney Disease Patients Undergoing Hemodialysis Unknown status NCT02452437 Phase 4 Oxycodone
11 Effect of Intravenous Acetadote on Incidence of Contrast Induced Nephropathy Unknown status NCT00939913 Phase 4 intravenous NAC;Placebo
12 Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease Unknown status NCT01094769 Phase 4 Moxonidine;Placebo
13 The Canadian Prevention of Renal and Cardiovascular Endpoints Trial Unknown status NCT00231803 Phase 4
14 Safety of Add on Aliskiren to Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin I Receptor Blocker (ARB) Treatment in Type 2 Diabetes With Nephropathy Unknown status NCT00949351 Phase 4 Aliskiren 300mg/d
15 Rituximab in Recurrent IgA Nephropathy Unknown status NCT02571842 Phase 4 Intravenous Rituximab;ACEI/ARB and corticosteroids
16 Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
17 The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease Unknown status NCT01157260 Phase 4 Kremezin
18 Intravenous Iron in Patients With Anemia of Chronic Kidney Disease Unknown status NCT00204256 Phase 4 Iron sucrose
19 Ezetimibe/Simvastatin Combination in Proteinuric Nephropathy Unknown status NCT00861731 Phase 4 simvastatin;EZE/simvastatin;EZE/simvastatin
20 Prevention of Contrast Nephropathy During Diagnostic Coronary Angiogram or PCI With Hydratation Based on LEVDP Unknown status NCT00584350 Phase 4
21 Anti-proteinuric Effect of Calcitriol in Non-diabetic Kidney Disease Patients Unknown status NCT01512862 Phase 4 Calcitriol;Placebo
22 Aldosterone in Diabetic Nephropathy Unknown status NCT00870402 Phase 4 Spironolactone;Placebo
23 Nephropathy In Type 2 Diabetes and Cardio-renal Events Unknown status NCT00535925 Phase 4 current therapy;irbesartan;ramipril;hydrochlorothiazide;furosemide;amlodipine;atenolol;doxazosin;clonidine;insulin;simvastatin;fibrate;erythropoietin;aspirin
24 Prevention of Contrast-Induced Nephropathy in Diabetic Patients With Undergoing Coronary Angiography Unknown status NCT00950079 Phase 4 Sodium bicarbonate;saline
25 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4 Calcitriol;Placebo
26 Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Among CKD and ACS Patients Unknown status NCT02459288 Phase 4 Clopidogrel first;Ticagrelor first
27 Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy Unknown status NCT01300273 Phase 4
28 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study) Unknown status NCT01869881 Phase 4 Anplag(Sarpogrelate);Placebo
29 Aspirin in the Prevention of Cardiovascular Events in Hemodialysis Patients Unknown status NCT01198379 Phase 4 aspirin;Placebo
30 Efficacy and Safety of Alprostadil Prevent Contrast Induced Nephropathy Unknown status NCT01722513 Phase 4 Alprostadil ﹠control
31 Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
32 Effect of Vitamin D Supplement on Osteoprotegin Expression and Disease Progression in Patients With Chronic Kidney Disease Stage 1 and 2 Unknown status NCT01561222 Phase 4 Calcitriol;placebo
33 Enhancing Dialysis Adequacy: Effects of Intradialytic Exercise Unknown status NCT01481688 Phase 4
34 The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Patients With Persistent Proteinuria Unknown status NCT00858299 Phase 4 valsartan
35 Reduction or Discontinuation of CNI's With Conversion to Everolimus-Based Immunosuppresion Unknown status NCT00443508 Phase 4 adding Certican to therapy;reducing Tacrolimus
36 Impact of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients Unknown status NCT00999258 Phase 4 sirolimus
37 Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease Unknown status NCT00235287 Phase 4 Candesartan and enalapril;candesartan and enalapril;candesartan and enalapril;candesartan and enalapril
38 Aliskiren and Muscle Sympathetic Nerve Activity Unknown status NCT00719316 Phase 4 Aliskiren
39 Far Infrared Therapy on AV Fistula Flow, Endothelial Function and Echocardiography in ESRD Patients Unknown status NCT01138254 Phase 4
40 Revascularization of Renal Artery Stenosis Versus Medical Therapy for the Treatment of Ischemic Nephropathy Unknown status NCT01023373 Phase 4 Medical treatment
41 Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease Unknown status NCT00852787 Phase 4 Digoxin immune fab;Placebo
42 A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD) Unknown status NCT01731301 Phase 4 Ribavirin;Peginterferon;Boceprevir
43 Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension Unknown status NCT00407680 Phase 4 Intensive therapy Valsartan,Fluvastatin
44 Effects of Spironolactone in Dialysis Unknown status NCT01128101 Phase 4 Spironolactone
45 Effect of Hydration With Sodium Bicarbonate for Long-Term Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing an Emergent Coronary Procedure Unknown status NCT00716001 Phase 4 N-acetylcysteine
46 Calcitriol in the Treatment of Immunoglobulin A Nephropathy Unknown status NCT00862693 Phase 4 Calcitriol
47 Safe Renal Function In Long Term Heart Transplanted Patients Unknown status NCT00505102 Phase 4 Everolimus
48 Practical Use of Advagraf de Novo After Kidney Transplantation According to Recipient Genetic Polymorphism Unknown status NCT02311010 Phase 4 Advagraf
49 A Study Comparing Outcomes of Kidney Transplants in Patients on Steroids Versus Those Who Discontinue Steroids Unknown status NCT00273559 Phase 4 prednisone
50 Effect of Sulodexide on Albuminuria in Chinese Type 2 Diabetic Patients Unknown status NCT01316068 Phase 4 intravenous use of sulodexide followed by oral use;use of sulodexide orally only

Search NIH Clinical Center for Kidney Disease

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: kidney diseases

Genetic Tests for Kidney Disease

Genetic tests related to Kidney Disease:

id Genetic test Affiliating Genes
1 Abnormality of the Kidney 29
2 Nephropathy 29

Anatomical Context for Kidney Disease

MalaCards organs/tissues related to Kidney Disease:

39
Kidney, Heart, Liver, Bone, Endothelial, Testes, Lung

Publications for Kidney Disease

Articles related to Kidney Disease:

(show top 50) (show all 3889)
id Title Authors Year
1
Leptospirosis Renal Disease: Emerging Culprit of Chronic Kidney Disease Unknown Etiology. ( 28926845 )
2017
2
Polycystic kidney disease: PMM2 mutation causes PKD and hyperinsulinism. ( 28435156 )
2017
3
The hypercoagulability paradox of chronic kidney disease: The role of fibrinogen. ( 28951066 )
2017
4
Urinary Microvesicle-Bound Uromodulin: A Potential Molecular Biomarker in Diabetic Kidney Disease. ( 28182086 )
2017
5
Aberrant Smad3 phosphoisoforms in cyst-lining epithelial cells in the cpk mouse, a model of autosomal recessive polycystic kidney disease. ( 28877884 )
2017
6
Incidence, Development, and Prognosis of Diabetic Kidney Disease in China: Design and Methods. ( 28091412 )
2017
7
A double-blind, randomized, placebo-controlled trial of combined calcitriol and ergocalciferol versus ergocalciferol alone in chronic kidney disease with proteinuria. ( 28088187 )
2017
8
The Challenges of Treating Cancer Patients on Hemodialysis, or With Chronic Kidney Disease. ( 28090621 )
2017
9
Novel pathologic scoring tools predict end-stage kidney disease in light chain (AL) amyloidosis. ( 28758811 )
2017
10
Restenosis in Hemodialytic Fistulas and Chronic Kidney Disease-Associated Vascular Disease: Two Pathologies Driven by Metakaryotic Stem Cells. ( 28535522 )
2017
11
The Potential Impact of Public Health Interventions in Preventing Kidney Disease. ( 28532553 )
2017
12
Grayscale ultrasound characteristics of autosomal dominant polycystic kidney disease severity - an adult and pediatric cohort study. ( 28856014 )
2017
13
Trimetazidine in the prevention of contrast-induced nephropathy in chronic kidney disease. ( 28532702 )
2017
14
Distinct effects of dietary flax compared to fish oil, soy protein compared to casein, and sex on the renal oxylipin profile in models of polycystic kidney disease. ( 28838555 )
2017
15
Polycystic kidney disease is significantly associated with dementia risk. ( 28855402 )
2017
16
A prospective cohort study of insomnia and chronic kidney disease in Japanese workers. ( 28534280 )
2017
17
Osteogenesis imperfecta complicated with renal hypoplasia leads to chronic kidney disease. ( 28317307 )
2017
18
Recent advances in the molecular diagnosis of polycystic kidney disease. ( 28952822 )
2017
19
Survey of owner subcutaneous fluid practices in cats with chronic kidney disease. ( 28948902 )
2017
20
Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study. ( 28810844 )
2017
21
Coincidence of Polysplenia, Kartagener Syndrome, Dorsal Pancreas Agenesis, and Polycystic Kidney Disease in an Adult. ( 28638261 )
2017
22
Dietary salt restriction is beneficial to the management of autosomal dominant polycysticA kidney disease. ( 27993381 )
2017
23
Bartonellosis in Chronic Kidney Disease: An Unrecognized and Unsuspected Diagnosis. ( 28884961 )
2017
24
Effect of renal denervation on kidney function in patients with chronic kidney disease. ( 28089459 )
2017
25
Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1I+,25-Dihydroxyvitamin D3) in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism on Hemodialysis. ( 28905271 )
2017
26
Serum sclerostin values are associated with abdominal aortic calcification and predict cardiovascular events in patients with chronic kidney disease stages 3-5D. ( 27165564 )
2017
27
Reducing VEGF-B Signaling Ameliorates Renal Lipotoxicity and Protects against Diabetic Kidney Disease. ( 28190774 )
2017
28
Comparison of MRI segmentation techniques for measuring liver cyst volumes in autosomal dominant polycystic kidney disease. ( 28846875 )
2017
29
High hepatitis C viral load and genotype 2 are strong predictors of chronic kidney disease. ( 28532708 )
2017
30
Collecting duct carcinoma of the kidney: Disease characteristics and treatment outcomes from the National Cancer Database. ( 28495554 )
2017
31
Traditional Medicines and Kidney Disease in Low- and Middle-Income Countries: Opportunities and Challenges. ( 28532554 )
2017
32
Chronic kidney disease in the BCR-ABL1-negative myeloproliferative neoplasm: a single-center retrospective study. ( 28298076 )
2017
33
Kidney disease and obesity: epidemiology, mechanisms and treatment. ( 28090083 )
2017
34
Acquired cystic kidney disease: an under-recognized condition in children with end-stage renal disease. ( 28444445 )
2017
35
Chronic Kidney Disease, Gender, and Access to Care: A Global Perspective. ( 28532558 )
2017
36
Sodium and fluid management in the conservative management of Chronic Kidney Disease. ( 28090763 )
2017
37
Correlations of Plasma Desphosphorylated Uncarboxylated Matrix Gla Protein with Vascular Calcification and Vascular Stiffness in Chronic Kidney Disease. ( 27951533 )
2017
38
Use of sofosbuvir in chronic kidney disease: Is it necessary? ( 28948751 )
2017
39
China Kidney Disease Network (CK-NET) 2014 Annual Data Report. ( 28532549 )
2017
40
Development of a novel chronic kidney disease mouse model to evaluate the progression of hyperphosphatemia and associated mineral bone disease. ( 28533541 )
2017
41
A 33year-old woman with calciphylaxis, diabetic kidney disease and abdominal pain. ( 28506812 )
2017
42
Glomerular Endothelial Mitochondrial Dysfunction Is Essential and Characteristic of Diabetic Kidney Disease Susceptibility. ( 27899487 )
2017
43
Trends in healthcare expenditure in United States adults with chronic kidney disease: 2002-2011. ( 28532412 )
2017
44
Kidney Disease Measures and Left Ventricular Structure and Function: The Atherosclerosis Risk in Communities Study. ( 28939714 )
2017
45
Diagnosis and Management of Acquired Cystic Kidney Disease and Renal Tumors in ESRD Patients. ( 28543535 )
2017
46
The China Kidney Disease Network (CK-NET): "Big Data-Big Dreams". ( 28532632 )
2017
47
CE: Improving Outcomes for Patients with Chronic Kidney Disease: Part 1. ( 28085685 )
2017
48
Focal segmental glomerulosclerosis in atypical polycystic kidney disease. ( 28063418 )
2017
49
Cystic kidney disease: A new osmoregulatory role for HNF-1I^. ( 28579614 )
2017
50
T1 vs. T2 weighted magnetic resonance imaging to assess total kidney volume in patients with autosomal dominant polycystic kidney disease. ( 28871393 )
2017